A phase 1 study of VMT01 for treating melanoma
Latest Information Update: 21 Jun 2023
At a glance
- Drugs VMT 01 (Primary)
- Indications Multiple myeloma
- Focus Diagnostic use; First in man
Most Recent Events
- 03 Feb 2022 New trial record
- 19 Apr 2021 Status changed from planning to recruiting, according to a Viewpoint Molecular Targeting media release.
- 19 Jan 2021 According to a Viewpoint Molecular Targeting media release, company awarded 5 million dollar in phase II SBIR grants from the National Institutes of Health - National Cancer Institute Jan 19, 2021. Second year of a 2 million dollar phase II SBIR funding to begin this trial.